SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 30.43% from the company’s previous close.

Separately, Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a research note on Tuesday.

SAB Biotherapeutics Stock Down 5.7 %

Shares of NASDAQ SABS opened at $4.60 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.45 and a current ratio of 5.45. The stock’s 50-day simple moving average is $4.94 and its two-hundred day simple moving average is $3.12. SAB Biotherapeutics has a twelve month low of $4.00 and a twelve month high of $14.50.

Hedge Funds Weigh In On SAB Biotherapeutics

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of SAB Biotherapeutics by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 996,132 shares of the company’s stock valued at $685,000 after purchasing an additional 19,194 shares during the last quarter. BVF Inc. IL bought a new position in shares of SAB Biotherapeutics during the 4th quarter valued at about $6,310,000. Pathstone Holdings LLC bought a new position in shares of SAB Biotherapeutics during the 4th quarter valued at about $348,000. Commodore Capital LP bought a new position in shares of SAB Biotherapeutics during the 4th quarter valued at about $1,259,000. Finally, Kestra Advisory Services LLC increased its position in shares of SAB Biotherapeutics by 319.0% during the 4th quarter. Kestra Advisory Services LLC now owns 88,000 shares of the company’s stock valued at $60,000 after purchasing an additional 67,000 shares during the last quarter. 7.82% of the stock is currently owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.